Table 1.

Current approved therapeutic strategies for IPF and LC treatment.

Therapy	Approved for IPF	Approved for LC
Nintedanib	Yes	Yes—In combination with docetaxel (second-line treatment) for ADC-NSCLC
Pirfenidone	Yes	No—Preclinical studies ongoing
Gefitinib	No—Early phase drug discovery study	Yes
Erlotinib	No—Early phase drug discovery study	Yes
Afatinib	No—Early phase drug discovery study	Yes
Imatinib	No—Strong recommendation against its use for IPF patients	Yes
Rovalpituzumab	No—Artesunate (pre-clinical studies)	Yes
Everolimus	No—Not effective in IPF	Yes
Nivolumab	Yes—Used for IPF-LC patients	Yes